N
← Back to Search
Sponsored

Accelerate Your Clinical Trial Recruitment

Reach thousands of high-intent patients matching your specific inclusion criteria.

Start Campaign
RECRUITING Phase 3 ClinicalTrials.gov

Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes

Sponsor: Novartis Pharmaceuticals • ClinicalTrials.gov ID: NCT07102628

Registry updated: 2026-09-16
Ad

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Check Eligibility →

Description

The purpose of this trial is to learn about the effects of inclisiran in people with serious heart conditions (acute coronary syndromes), when this treatment is started early after hospital admission. To do this, researchers will test the effects of inclisiran compared to placebo, when given with standard treatment.

Interventions

  • Placebo (Drug)
    The participants will receive placebo subcutaneous at randomization (Day 1, Baseline visit) and Day 90
  • Inclisiran (Drug)
    The participants will receive Inclisiran sodium 300 mg subcutaneous at randomization (Day 1, Baseline visit) and Day 90

Eligibility criteria

Inclusion Criteria: Participant eligible for inclusion in this study must meet all the following criteria: At Screening: 1. Signed informed consent must be obtained prior to participation in the study. 2. Males and females, ≥18 years of age at the time of providing written informed consent. 3. Ability to understand study's requirements and provide informed consent and comply with all required study procedures. 4. Hospitalization for a ACS event (STEMI or NSTEMI). 5. Receiving treatment for the qualifying ACS event, according to clinical judgement, by means of medical treatment alone or percutaneous coronary revascularization. 6. Had a successful PCI (with or without stent) for the qualifying event if a PCI was required. 7. LDL-C values measured by the local lab either at the Screening visit or results from local lab tests performed prior to ICF signature, strictly as part of the routine clinical practice in this emergency ACS setting and not older than 2 days of: * LDL-C ≥70 mg/dL in participant previously treated with high-intensity statin (atorvastatin ≥40 mg/day or rosuvastatin ≥20 mg/day) or equivalent as per national guidelines and local regulation for at least 4 weeks before screening or * LDL-C ≥80 mg/dL in participant previously treated with low/moderate-intensity statin for at least 4 weeks before screening or * LDL-C ≥100 mg/dL in participant previously not treated with statins for at least 4 weeks before screening, or who never received statins (including statin intolerant participants). At Randomization: 8. The participant must have a Baseline fasting LDL-C ≥70 mg/dL (local lab assessment) to be eligible for randomization. 9. Randomization within 7 days (≤ 7 days) following hospital admission for the qualifying ACS event and before/at discharge. Exclusion Criteria: Participant meeting any of the following criteria is not eligible for inclusion in this study. Only for Japan: For exclusion criteria 6, investigator judgment should be documented in the source data document. 1. Participant who is clinically unstable during hospitalization for the qualifying ACS event, defined by any of the following events within 24 hours prior to randomization: * Hemodynamic instability: hypotension, defined as sustained systolic blood pressure of \<90 mmHg due to cardiac failure with associated symptoms requiring inotropes * Sustained arrhythmic events such as: ventricular storm (e.g., torsade, ventricular tachycardia, ventricular flutter) not resolved before randomization * Cardiogenic shock or mechanical complication of myocardial infarction * New York Heart Association (NYHA) class IV heart failure * Left ventricular ejection fraction \<20% at randomization (after all treatment procedures, based on the latest assessment of the LVEF using invasive or non-invasive assessment modalities) * Uncontrolled severe hypertension: systolic blood pressure \>180 mmHg or diastolic blood pressure \>110 mmHg prior to randomization despite antihypertensive therapy. 2. Participant who has undergone or is scheduled to undergo CABG for treatment of the qualifying ACS event. 3. Active liver disease defined as: (i) any known current infectious, neoplastic, or metabolic pathology of the liver or (ii) alanine aminotransferase (ALT) elevation \>3x ULN or aspartate aminotransferase (AST) elevation \>3x ULN, or total bilirubin elevation \>2x ULN (except participant with Gilbert's syndrome) at the Screening visit, in the context of an ACS, and assessed as related to the index event and/or treatment procedures (such as PCI). Eligibility will be based on Investigator's judgement for participant who will be randomized. 4. Renal insufficiency (eGFR \<30 mL/min/1.73m2) at the Screening visit. 5. Fasting triglycerides value \>400 mg/dL (4.52 mmol/L; assessed by local labs) at randomization visit. 6. Participant, who based on the Investigator's judgement, could reach the LDL-C target value of \<55 mg/dL after 4 weeks on statin treatment only. 7. Secondary hypercholesterolemia (based on medical history). 8. Homozygous familial hypercholesterolemia (based on medical history). 9. Participant on apheresis at the Screening visit or for whom an apheresis is planned during study (from Day 1 to EOS). 10. Ongoing or medical history of myopathy at the Screening visit. 11. CK values ≥5x ULN at Screening visit and confirmed by repeat test during Screening (local lab) , in the context of an ACS, and assessed as related to the index event and/or treatment procedures (such as PCI) eligibility will be based on Investigator's judgement for participant who will be randomized (who will be switched to or initiated on the protocol-specified dose of high-intensity statin of atorvastatin ≥40 mg QD or rosuvastatin ≥20 mg QD). Unless a more stringent CK value threshold is mandated by a local regulatory authority (e.g., ≥3x ULN in Korea according to MFDS internal guideline).

Conditions

Acute Coronary Syndrome

Locations

  • Novartis Investigative Site — Capital Federal, Buenos Aires, Argentina
  • Novartis Investigative Site — Garran, Australian Capital Territory, Australia
  • Novartis Investigative Site — Clayton, Victoria, Australia
  • Novartis Investigative Site — Edmonton, Alberta, Canada
  • Novartis Investigative Site — Hamilton, Ontario, Canada
  • Novartis Investigative Site — London, Ontario, Canada
  • Novartis Investigative Site — Newmarket, Ontario, Canada
  • Novartis Investigative Site — Montreal, Quebec, Canada
  • Novartis Investigative Site — Québec, Quebec, Canada
  • Novartis Investigative Site — Beijing, China, China
  • Novartis Investigative Site — Guangzhou, Guangdong, China
  • Novartis Investigative Site — Luoyang, Henan, China
  • Novartis Investigative Site — Xuzhou, Jiangsu, China
  • Novartis Investigative Site — Nanchang, Jiangxi, China
  • Novartis Investigative Site — Wenzhou, Zhejiang, China
  • Novartis Investigative Site — Beijing, China
  • Novartis Investigative Site — Beijing, China
  • Novartis Investigative Site — Fuzhou, China
  • Novartis Investigative Site — Guangzhou, China
  • Novartis Investigative Site — Guangzhou, China
  • Novartis Investigative Site — Jining, China
  • Novartis Investigative Site — Shanghai, China
  • Novartis Investigative Site — Shanghai, China
  • Novartis Investigative Site — Tianjin, China
  • Novartis Investigative Site — Chambray-lès-Tours, France
  • Novartis Investigative Site — Montpellier, France
  • Novartis Investigative Site — Nantes, France
  • Novartis Investigative Site — Pessac, France
  • Novartis Investigative Site — Poitiers, France
  • Novartis Investigative Site — Leipzig, Saxony, Germany
  • Novartis Investigative Site — Coburg, Germany
  • Novartis Investigative Site — Erfurt, Germany
  • Novartis Investigative Site — Essen, Germany
  • Novartis Investigative Site — Hennigsdorf, Germany
  • Novartis Investigative Site — Kiel, Germany
  • Novartis Investigative Site — Hong Kong, Hong Kong, Hong Kong
  • Novartis Investigative Site — Hong Kong, Hong Kong
  • Novartis Investigative Site — Pécs, Baranya, Hungary
  • Novartis Investigative Site — Debrecen, Hajdu Bihar Megye, Hungary
  • Novartis Investigative Site — Budapest, Hungary
  • Novartis Investigative Site — Budapest, Hungary
  • Novartis Investigative Site — Miskolc, Hungary
  • Novartis Investigative Site — Belagavi, Karnataka, India
  • Novartis Investigative Site — Mumbai, Maharashtra, India
  • Novartis Investigative Site — Nashik, Maharashtra, India
  • Novartis Investigative Site — Bikaner, Rajasthan, India
  • Novartis Investigative Site — Chikushino-shi, Fukuka, Japan
  • Novartis Investigative Site — Kitakyushu, Fukuoka, Japan
  • Novartis Investigative Site — Kamakura, Kanagawa, Japan
  • Novartis Investigative Site — Sagamihara, Kanagawa, Japan
  • Novartis Investigative Site — Bunkyo Ku, Tokyo, Japan
  • Novartis Investigative Site — Gdansk, Poland
  • Novartis Investigative Site — Katowice, Poland
  • Novartis Investigative Site — Krakow, Poland
  • Novartis Investigative Site — Opole, Poland
  • Novartis Investigative Site — Seoul, Seoul, South Korea
  • Novartis Investigative Site — Seoul, South Korea
  • Novartis Investigative Site — Santiago Compostela, A Coruna, Spain
  • Novartis Investigative Site — Huelva, Andalusia, Spain
  • Novartis Investigative Site — El Palmar, Murcia, Spain
  • Novartis Investigative Site — Las Palmas GC, Spain
  • Novartis Investigative Site — Madrid, Spain
  • Novartis Investigative Site — Madrid, Spain
  • Novartis Investigative Site — Salamanca, Spain
  • Novartis Investigative Site — Seville, Spain
  • Novartis Investigative Site — Valencia, Spain
  • Novartis Investigative Site — Bern, Switzerland
  • Novartis Investigative Site — Geneva, Switzerland
  • Novartis Investigative Site — Lucerne, Switzerland
Sponsored

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record